Human TERT promoter mutations as a prognostic biomarker in glioma
Branka Powter(Ingham Institute), Therese M. Becker(Liverpool Hospital), Eng‐Siew Koh(Liverpool Hospital), Joseph W. Po(Camden and Campbelltown Hospitals), Sarah A. Jeffreys(Camden and Campbelltown Hospitals), Heena Sareen(UNSW Sydney), Kieran F. Scott(Ingham Institute), Tara L. Roberts(Camden and Campbelltown Hospitals), Daniel Brungs(University of Wollongong), Joey Yusof Vessey(Liverpool Hospital), Adam Cooper(Liverpool Hospital), Mila Sajinovic(Ingham Institute), Paul de Souza(St. George Hospital)
Cited by 73
Related Papers
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2015|1.4k
HIN-200 Proteins Regulate Caspase Activation in Response to Foreign Cytoplasmic DNA
|Science|2009|822
AIM2 and NLRP3 inflammasomes activate both apoptotic and pyroptotic death pathways via ASC
|Cell Death and Differentiation|2013|507